
Veria Vacchiano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4122857/publications.pdf Version: 2024-02-01



VERIA VACCHIANO

#	Article	IF	CITATIONS
1	Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1166-1174.	1.9	99
2	Early neurological manifestations of hospitalized COVID-19 patients. Neurological Sciences, 2020, 41, 2029-2031.	1.9	72
3	In Vivo Diagnosis of Synucleinopathies. Neurology, 2021, 96, e2513-e2524.	1.1	63
4	Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis. Journal of Neurology, 2020, 267, 1699-1708.	3.6	39
5	Uric acid: a potential biomarker of multiple sclerosis and of its disability. Clinical Chemistry and Laboratory Medicine, 2015, 53, 753-9.	2.3	38
6	Plasma and CSF Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: A Cross-Sectional and Longitudinal Study. Frontiers in Aging Neuroscience, 2021, 13, 753242.	3.4	33
7	Lesion Load May Predict Long-Term Cognitive Dysfunction in Multiple Sclerosis Patients. PLoS ONE, 2015, 10, e0120754.	2.5	31
8	The autonomic innervation of hairy skin in humans: an in vivo confocal study. Scientific Reports, 2019, 9, 16982.	3.3	28
9	Antibodies to neuronal surface antigens in patients with a clinical diagnosis of neurodegenerative disorder. Brain, Behavior, and Immunity, 2021, 96, 106-112.	4.1	16
10	Diagnostic and Prognostic Value of Conventional Brain MRI in the Clinical Work-Up of Patients with Amyotrophic Lateral Sclerosis. Journal of Clinical Medicine, 2020, 9, 2538.	2.4	14
11	First-line disease-modifying drugs in relapsing–remitting multiple sclerosis: an Italian real-life multicenter study on persistence. Current Medical Research and Opinion, 2018, 34, 1803-1807.	1.9	13
12	Functional MRI study in a case of Charles Bonnet syndrome related to LHON. BMC Neurology, 2019, 19, 350.	1.8	12
13	Targeted sequencing panels in Italian ALS patients support different etiologies in the ALS/FTD continuum. Journal of Neurology, 2021, 268, 3766-3776.	3.6	12
14	JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level. Therapeutics and Clinical Risk Management, 2014, 10, 807.	2.0	11
15	The Effect of Curcumin on Idiopathic Parkinson Disease: A Clinical and Skin Biopsy Study. Journal of Neuropathology and Experimental Neurology, 2022, 81, 545-552.	1.7	11
16	Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship. Clinical Neuropharmacology, 2018, 41, 171-176.	0.7	10
17	Brain metabolic correlates of apathy in amyotrophic lateral sclerosis: An 18Fâ€FDGâ€positron emission tomography stud. European Journal of Neurology, 2021, 28, 745-753.	3.3	10
18	Epidemiological, Clinical and Genetic Features of ALS in the Last Decade: A Prospective Population-Based Study in the Emilia Romagna Region of Italy. Biomedicines, 2022, 10, 819.	3.2	10

VERIA VACCHIANO

#	Article	IF	CITATIONS
19	Arthritic psoriasis during natalizumab treatment: a case report and review of the literature. Neurological Sciences, 2018, 39, 181-183.	1.9	8
20	Combined brain positron emission tomography/magnetic resonance imaging in GABA A receptor encephalitis. European Journal of Neurology, 2019, 26, e88-e89.	3.3	7
21	Vitamin K cream reduces reactions at the injection site in patients with relapsing–remitting multiple sclerosis treated with subcutaneous interferon beta – VIKING study. Multiple Sclerosis Journal, 2015, 21, 1215-1216.	3.0	6
22	Denervation findings on EMG in amyotrophic lateral sclerosis and correlation with prognostic milestones: Data from a retrospective study. Clinical Neurophysiology, 2020, 131, 2017-2022.	1.5	6
23	Exacerbation of myasthenia gravis after amoxicillin therapy: a case series. Neurological Sciences, 2020, 41, 2255-2257.	1.9	6
24	Quality of life assessment in adult spinal muscular atrophy patients treated with nusinersen. Journal of Neurology, 2022, 269, 3264-3275.	3.6	6
25	Teeth loss after teriflunomide treatment: Casual or causal? A short case series. Multiple Sclerosis and Related Disorders, 2018, 24, 120-122.	2.0	5
26	Broadening the Spectrum of Adulthood X-Linked Adrenoleukodystrophy: A Report of Two Atypical Cases. Frontiers in Neurology, 2019, 10, 70.	2.4	5
27	Neurological involvement in Ile68Leu (p.Ile88Leu) ATTR amyloidosis: not only a cardiogenic mutation. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 173-181.	3.0	5
28	Clinical Reasoning: A 58-year-old man with distal hand weakness. Neurology, 2019, 92, e1395-e1400.	1.1	4
29	The m.3890G>A/MT-ND1 mtDNA rare pathogenic variant: Expanding clinical and MRI phenotypes. Mitochondrion, 2021, 60, 142-149.	3.4	4
30	CSF Heavy Neurofilament May Discriminate and Predict Motor Neuron Diseases with Upper Motor Neuron Involvement. Biomedicines, 2021, 9, 1623.	3.2	4
31	Subcutaneous immunoglobulin treatment and thromboembolic risk. Annals of Allergy, Asthma and Immunology, 2018, 120, 433-435.	1.0	3
32	Movement Disorders Associated with GABA A Receptor Encephalitis: A Video Case Report. Movement Disorders Clinical Practice, 2020, 7, 681-683.	1.5	3
33	The clinical spectrum of multisystem proteinopathy: Data from a neurodegenerative cohort. Journal of the Neurological Sciences, 2021, 426, 117478.	0.6	3
34	Prognostic value of EMG genioglossus involvement in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2021, 132, 2416-2421.	1.5	3
35	Needle electromyography of craniobulbar muscles in patients with amyotrophic lateral sclerosis: Direct comparison between genioglossus and masseter muscles. Clinical Neurophysiology, 2021, 132, 744-745.	1.5	2
36	Subcutaneous immunoglobulin treatment and leucopenia in acquired demyelinating peripheral neuropathies. European Journal of Neurology, 2019, 26, e80-e81.	3.3	1

#	Article	IF	CITATIONS
37	6MWT as measure of motor function and endurance in SMA type 3 patients treated with nusinersen. Journal of the Neurological Sciences, 2021, 429, 119385.	0.6	Ο
38	Efficacy and safety of rituximab therapy in patients with autoimmune neurological disorders. Journal of the Neurological Sciences, 2021, 429, 118822.	0.6	0
39	Pyramidal pathway changes at conventional brain 3†T-MRI in patients with hereditary spastic paraplegia. Journal of the Neurological Sciences, 2021, 429, 118259.	0.6	Ο
40	A sight into the elderly ALS patients in Emilia Romagna region: Epidemiological and clinical features of late onset ALS in a prospective population-based study. Journal of the Neurological Sciences, 2021, 429, 119390.	0.6	0